WO2002055656A3 - GENE THERAPY USING TGF-$g(b) - Google Patents

GENE THERAPY USING TGF-$g(b) Download PDF

Info

Publication number
WO2002055656A3
WO2002055656A3 PCT/US2001/047588 US0147588W WO02055656A3 WO 2002055656 A3 WO2002055656 A3 WO 2002055656A3 US 0147588 W US0147588 W US 0147588W WO 02055656 A3 WO02055656 A3 WO 02055656A3
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
cartilage
gene therapy
covered
cell
Prior art date
Application number
PCT/US2001/047588
Other languages
French (fr)
Other versions
WO2002055656A2 (en
Inventor
Moon Jong Noh
Kyoung Ae Kang
Kwan Hee Lee
Original Assignee
Tissuegene, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/707,900 external-priority patent/US7338655B1/en
Application filed by Tissuegene, Inc. filed Critical Tissuegene, Inc.
Priority to AU2002243307A priority Critical patent/AU2002243307A1/en
Publication of WO2002055656A2 publication Critical patent/WO2002055656A2/en
Publication of WO2002055656A3 publication Critical patent/WO2002055656A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The subject invention is related to a cell-mediated gene therapy treatment for orthopedic disease using a member belonging to the transforming growth factor-β (TGF-β) superfamily. TGF-β gene therapy as a new treatment method for degenerative arthritis is demonstrated. After transfection of TGF-βcDNA expression vectors into fibroblasts (NIH 3T3-TGF-β1), the cells were injected into rabbit achilles tendon and knee joints with artificaslly-made cartilage defects. Intratendinous injections were performed to determine the optimal concentration of in vivo expression. Partially defected cartilage model was made to stimulate degenerative arthritis of the knee joint. The partial cartilage defect treated with the cell-mediated gene therapy procedure was covered by newly formed hyaline cartilage which indicates the cells survived and stimulated matrix formation in this area. Completely denuded cartilage areas were covered by fibrous collagen.
PCT/US2001/047588 2000-11-08 2001-11-07 GENE THERAPY USING TGF-$g(b) WO2002055656A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002243307A AU2002243307A1 (en) 2000-11-08 2001-11-07 Gene therapy using tgf-beta

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/707,900 2000-11-08
US09/707,900 US7338655B1 (en) 1999-06-30 2000-11-08 Gene therapy using TGF-β

Publications (2)

Publication Number Publication Date
WO2002055656A2 WO2002055656A2 (en) 2002-07-18
WO2002055656A3 true WO2002055656A3 (en) 2003-01-30

Family

ID=24843600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/047588 WO2002055656A2 (en) 2000-11-08 2001-11-07 GENE THERAPY USING TGF-$g(b)

Country Status (2)

Country Link
AU (1) AU2002243307A1 (en)
WO (1) WO2002055656A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4033400B2 (en) * 2002-03-12 2008-01-16 ティシュージーン，インク Cartilage regeneration using chondrocytes and TGF-β
JPWO2005073365A1 (en) * 2004-01-29 2007-09-13 株式会社 ジャパン・ティッシュ・エンジニアリング Method of treating cells for transplantation, cell suspension, prosthesis for transplantation, and method of treating damaged site

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021589A2 (en) * 1997-10-29 1999-05-06 Axel Wilhelm August Baltzer Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
WO2000066177A1 (en) * 1999-05-03 2000-11-09 Tissuegene Co. GENE THERAPY USING TGF-$g(b)
US6315992B1 (en) * 1999-06-30 2001-11-13 Tissuegene Co. Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021589A2 (en) * 1997-10-29 1999-05-06 Axel Wilhelm August Baltzer Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
WO2000066177A1 (en) * 1999-05-03 2000-11-09 Tissuegene Co. GENE THERAPY USING TGF-$g(b)
US6315992B1 (en) * 1999-06-30 2001-11-13 Tissuegene Co. Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BAKKER ET AL.: "Overexpression of active TFG-beta-1 in the murine knee joint: Evidence for synovial-layer-dependent chondro-osteophyte formation", OSTEOARTHRITIS AND CARTILAGE, vol. 9, no. 2, February 2001 (2001-02-01), pages 128 - 136, XP002952703 *
CHERNAJOVSKY ET AL.: "Pathogenic lymphoid cells engineered to express TFG.beta.1 ameliorate disease in a collagen-induced arthritis model", GENE THERAPY, vol. 4, no. 6, 1997, pages 553 - 559, XP002952705 *
DUPREZ ET AL.: "Overexpression of BMP-2 and BMP-4 alters the size and shape of developing skeletal elements in the chick limb", MECHANISM OF DEVELOPMENT, vol. 57, no. 2, July 1996 (1996-07-01), pages 145 - 157, XP002092482 *
MOELLER ET AL.: "Gentherapeutische Ansaetze in der arthrosebehandlung", ORTHOPAEDE, vol. 28, 1999, pages 76 - 81, XP002952702 *
PRUD'HOMME ET AL.: "Anticytokine gene therapy of autoimmune diseases", EXPERT OPIN. BIOL. THER., vol. 1, no. 3, May 2001 (2001-05-01), pages 359 - 373, XP002952706 *
SHULER ET AL.: "Increased matrix synthesis following adenoviral transfer of a transforming growth factor beta1 gene into articular chondrocytes", J. ORTHOPEAEDIC RES., vol. 18, no. 4, July 2000 (2000-07-01), pages 585 - 592, XP002952704 *
SONG ET AL.: "Plasmid DNA encoding transforming growth factor-beta-1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model", J. CLIN. INVEST., vol. 101, no. 12, 15 June 1998 (1998-06-15), pages 2615 - 2621, XP002933068 *

Also Published As

Publication number Publication date
AU2002243307A1 (en) 2002-07-24
WO2002055656A2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
DE69814352T2 (en) MATRIXLESS OSTEOGENIC DEVICES AND IMPLANTS AND METHOD FOR THE USE THEREOF
AU699918B2 (en) Methods and compositions for healing and repair of connective tissue attachment
CA1341610C (en) Osteogenic polypeptides
Milano et al. The effect of platelet rich plasma combined with microfractures on the treatment of chondral defects: an experimental study in a sheep model
DE69927512T2 (en) USE OF OP-1 FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE REPAIR OF NON-BODY CORNEAL DEFECTS OF ANIMALS
RU2421173C2 (en) Method of meniscus rupture reparation
US8173149B2 (en) Method for producing porous β-tricalcium phosphate granules
ES2209819T3 (en) PROCEDURE AND COMPOSITIONS FOR THE CICATRIZATION AND REPAIR OF THE ARTICULAR CARTILAGO.
Hrabchak et al. Assessment of biocompatibility and initial evaluation of genipin cross-linked elastin-like polypeptides in the treatment of an osteochondral knee defect in rabbits
JP2001516262A (en) Osteogenic device and its use for bone repair
US10525105B2 (en) Peptide for repairing cartilage and treating osteoarthritis
JP2005508217A (en) Pore former for orthopedic cement
KR20110067035A (en) Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
Ma et al. Sustained delivery of glial cell-derived neurotrophic factors in collagen conduits for facial nerve regeneration
Lietman et al. The temporal sequence of spontaneous repair of osteochondral defects in the knees of rabbits is dependent on the geometry of the defect
Glimcher et al. Changes in tissue morphology and collagen composition during the repair of cortical bone in the adult chicken.
de Mulder et al. Similar hyaline-like cartilage repair of osteochondral defects in rabbits using isotropic and anisotropic collagen scaffolds
US7347872B2 (en) Connective tissue substitutes, method of preparation and uses thereof
WO2002055656A3 (en) GENE THERAPY USING TGF-$g(b)
Uthamanthil et al. In vivo study on the short‐term effect of radiofrequency energy on chondromalacic patellar cartilage and its correlation with calcified cartilage pathology in an equine model
KR101863532B1 (en) Manufacturing and use method of cartilage tissue repair composition
KR100704537B1 (en) Compositions for healing and repair of articular cartilage
EP4149576A1 (en) Composite product for the osteoarticular regeneration of cartilage lesion
Oesser et al. Impact of Collagen Fragments on the Synthesis and Degradation of the Extracellular Matrix of Cartilage Tissue
Grigolo et al. Tissue engineering applications: cartilage lesions repair by the use of autologous chondrocytes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP